---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-26-000034"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2026-06-11T11:06:57+00:00"
generated_at: "2026-06-11T11:10:10.279198+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nurix reports Phase 1a/1b data for bexobrutideg: ORR 83% in R/R CLL, 92.9% in earlier-line

## Summary
- Phase 1a ORR 83.0% (47 evaluable), median PFS 22.1 months; median 4 prior lines.
- Phase 1b Cohort 5 (BTKi-treated, BCL2i-naïve): ORR 92.9% at 5.2 months follow-up; 18/19 on treatment.
- Phase 1b Cohort 15 (BTKi-naïve, incl. treatment-naïve): ORR 84.2% at 4.9 months; 19/20 on treatment.
- Safety: well-tolerated, no dose-limiting toxicities, no treatment-related Grade 5 events; AE discontinuation 5.6%.
- Company plans Phase 3 monotherapy program and has Roche collaboration.

## SEC filing metadata
- accession: 0001549595-26-000034
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2026-06-11T11:06:57+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000034/0001549595-26-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000034/nrix-20260611.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-26-000034
- JSON: https://secwatch.observer/filing/0001549595-26-000034.json
- Plain text: https://secwatch.observer/filing/0001549595-26-000034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.